By Andrew Silver
SHANGHAI (Reuters) – At least 11 generic versions of Novo Nordisk’s popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy’s active ingredient semaglutide in China.
COMPANIES WHICH COMPLETED PHASE 3
Hangzhou Jiuyuan Gene Engineering: It has said its drug has “similar clinical efficacy and safety” as Ozempic
Livzon Pharmaceutical Group
COMPANIES THAT FINISHED RECRUITING FOR PHASE 3 TRIALS
Chongqing Chenan Biopharmaceutical/Shanghai Bovax Biotechnology
COMPANIES RECRUITING PARTICIPANTS FOR PHASE 3 TRIALS
CSPC Pharmaceutical Group
Huadong Medicine/Peg-Bio Biopharm
Sino Biopharmaceutical Limited subsidiary
Qilu Pharmaceutical
COMPANIES THAT HAVE YET TO START RECRUITING
Brilliant Pharmaceuticals
QL Biopharm
Sihuan Pharmaceutical subsidiary
United Laboratories
Source: records from
(Reporting by Andrew Silver; Editing by Muralikumar Anantharaman)
Comments